Evidence map›Paper›PMID 38496632›Full record

ArticleResearch square2024

Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node.

Yang Shen, Erin Connolly, Meili Aiello, Chengjing Zhou, Prasanthi Chappa, Haorui Song, Patan Tippitak, Tarralyn Clark, Maria Cardenas, Nataliya Prokhnevska and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 3 institutions in 3 countries.

Yang ShenDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Erin ConnollyBioinformatics Graduate Program, Georgia Institute of Technology, Atlanta, GA, USA.
Meili AielloDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Chengjing ZhouDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Prasanthi ChappaDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Haorui SongDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0009-0005-6940-9298
Patan TippitakDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Tarralyn ClarkDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Maria CardenasDepartment of Urology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0002-8566-9576
Nataliya ProkhnevskaMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai (ICMMS), New York City, NY, USA.
Annapaola MarinielloDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Meghana S PagadalaMedical Scientist Training Program, University of California San Diego, La Jolla, CA USA.
Vishal R DhereDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Sarwish RafiqDepartment of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0002-9295-3065
Aparna H KesarwalaDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0001-8297-9643
Alexandre OrthweinDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0002-7350-3413
Susan N ThomasGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Mohammad K KhanDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
J Brandon DixonGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0003-0351-4587
Gregory B LesinskiDepartment of Hematology and Medical Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0002-8787-7678
Michael C LoweDepartment of Surgery and Winship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID 0000-0003-4853-7352
Haydn KissickDepartment of Urology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0001-7624-5598
David S YuDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Chrystal M PaulosDepartment of Surgery and Winship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID 0000-0002-0784-2601
Nicole C SchmittDepartment of Otolaryngology - Head and Neck Surgery and Winship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID 0000-0002-0571-3531
Zachary S BuchwaldDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Emory University · USGeorgia Institute of Technology · USUniversity of Geneva · CH

Funding

T32 Research Training Program in ImmunoEngineeringT32EB021962 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI JULIA E BABENSEE · 2017 to 2026
$1.9M
The role of stem-like CD8 T-cells in the abscopal responseK08CA270401 · NCI · EMORY UNIVERSITY · PI Zachary Scott Buchwald · 2023 to 2026
$970k
NCI NIH HHS K08 CA270401NIBIB NIH HHS T32 EB021962
6 · The paper itself

Abstract

Radiotherapy (RT) and anti-PD-L1 synergize to enhance local and distant (abscopal) tumor control. However, clinical results in humans have been variable. With the goal of improving clinical outcomes, we investigated the underlying synergistic mechanism focusing on a CD8+ PD-1+ Tcf-1+ stem-like T cell subset in the tumor-draining lymph node (TdLN). Using murine melanoma models, we found that RT + anti-PD-L1 induces a novel differentiation program in the TdLN stem-like population which leads to their expansion and differentiation into effector cells within the tumor. Our data indicate that optimal synergy between RT + anti-PD-L1 is dependent on the TdLN stem-like T cell population as either blockade of TdLN egress or specific stem-like T cell depletion reduced tumor control. Together, these data demonstrate a multistep stimulation of stem-like T cells following combination therapy which is initiated in the TdLN and completed in the tumor.

Indexed as

abscopal effectcheckpoint blockadeimmunotherapyPD-1PD-L1Radiationstem-like T cellsTcf-1tumor-draining lymph node

Identifiers

PMID38496632
PMCPMC10942568
OpenAlexW4392515756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.